Concurrent HLA-related response factors mediate recombinant hepatitis B vaccine major adverse events

Autoimmunity

Volumn 38, Issue 2, 2005, Pages 181-194

  Miller, J D ^a   Whitehair, L H ^b,c  

^a MAINE MEDICAL CENTER   (United States)

^b BOEING COMPANY   (United States)

^c NONE   (United States)

Author keywords

Adverse event; Autoimmunity; Hepatitis B; HLA; Pathogenesis; Vaccine

Indexed keywords

AUTOANTIBODY; DNA; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ALLELE; AUTOIMMUNITY; CASE REPORT; CELL ACTIVATION; CELL SECRETION; CELLULAR IMMUNITY; CROHN DISEASE; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DNA FINGERPRINTING; GENE AMPLIFICATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEPATITIS B; HUMAN; HYPOTHESIS; IDIOPATHIC DISEASE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MALE; OPTIC NERVE DISEASE; PANCYTOPENIA; POLYARTHRITIS; PROBABILITY; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; VALIDATION PROCESS; VASCULITIS;

ALLELES; CHILD; CROHN DISEASE; HEPATITIS B; HEPATITIS B VACCINES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-DR ANTIGENS; HUMANS; MALE;

EID: 21044440889     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/08916930500095504     Document Type: Review

References (149)

1. Incao P. Testimony to Ohio House of Representatives 1999 Mar 1. Available: www.garynull.com/Documents/niin/incao_hepatitis_b_vaccination_te.htm via the INTERNET. Accessed: Jan 25
2. Centers for Disease Control and Prevention., Vaccine Safety Datalink (VSD) Project, Completed and Current Studies, December, 2000 - November, 2003 - [cited 2005 Jan 12]; Available from: http//www.cdc.gov/nip/vacsafe/vsd/research.htm
3. Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996; 135:355-362.
4. Lucchinetti CF, Kiers L, O'Duffy A, Gomez MR, Cross S, Leavitt JA, O'Brien P, Rodriguez M. Risk factors for developing multiple sclerosis after childhood optic neuritis. Neurology 1997;49:1413-1418.
5. Mineta M, Tanimura M, Tana T, Yssel H, Kashiwagi S, Sasazuki T. Contribution of HLA class I and class II alleles to the regulation of antibody production to hepatitis B surface antigen in humans. Int Immunol 1996;8:525-531.
6. Caillat-Zucman S, Gimenez JJ, Wambergue F, Albouze G, Lebkiri B, Naret C, Moynot A, Jungers P, Bach JF, Distinct HLA class II. alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 1998;53:1626-1630.
7. Hohler T, Meyer CU, Notghi A, Stradmann-Bellinghausen B, Schneider PM, Starke R, Zepp F, Sanger R, Clemens R, Meyer zum Buschenfelde KH, Rittner C. The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol 1998;59:212-218.
8. Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, Awdeh Z, Schlossman SF, Alper CA, Yunis EJ. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 1991;173:531-538.
9. Schuenke KW, Cook RG, Rich RR. Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients. Hum Immunol 1998;59:783-793.
10. Lango-Warensjo A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. Tissue Antigens 1998;52:374-380.
11. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schilcht HJ, Vitiello A, Chesnut R, Person JL, Redeker AG, et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993;150:4659-4671.
12. Usonis V, Kuhnl P, Brede HD, Doerr HW. Humoral immune response after hepatitis-B-vaccination: Kinetics of anti-HBs antibodies and demonstration of HLA antigens. Zentralb Bakteriol Mikrobiol Hyg [A] 1986;262:377-384.
13. Thio CL, Thomas DL, Karacki P, Gao X, Marti D, Kaslow RA, Goedert JJ, Hilgartner M, Strathdee SA, Duggal P, O'Brien SJ, Astemborski J, Carrington M. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol 2003;77:12083-12087.
14. Achiron LR. Postinfectious hepatitis B optic neuritis. Optom Vis Sci 1994;71:53-56.
15. Heermann KH, Gerlich WH. Immunology of hepatitis B infections. Rheumatol Int 1989;9:167-173.
16. Taneja V, Mehra NK, Chandershekaran AN, Ahuja RK, Singh YN, Malaviya AN. HLA-DR4-DQw8, but not DR4-DQw7 haplotypes occur in Indian patients with rheumatoid arthritis. Rheumatol Int 1992;11:251-255.
17. Truedsson L, Sturfelt G, Johansen P, Nived O, Thuresson B. Sharing of MHC haplotypes among patients with systemic lupus erythematosus from unrelated Caucasian multicase families: Disease associations with the extended haplotype [HLA-B8, SC01, DR17]. J Rheumatol 1995;22:1852-1861.
18. Davatchi F, Nikbin B, Ala F. Histocompatibility antigens (HLA) in rheumatic diseases in Iran. J Rheumatol Suppl 1977;3:36-38.
19. Davies ML, Young SP, Welsh K, Bunce M, Wordsworth BP, Davies KA, Wagenknecht DR, Taylor E, Gordon C, Jobson S, Briggs D, Bowman SJ. Immune response to native beta(2)-glycoprotein I in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Rheumatology(Oxford) 2002;41:395-400.
20. Arnett FC, Thiagarajan P, Ahn C, Reveille JD. Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II antigens in three ethnic groups. Arthritis Rheum 1999; 42:268-274.
21. Galeazzi M, Sebastiani GD, Tincani A, Piette JC, Allegri F, Morozzi G, Bellisai F, Scorza R, Ferrrara GB, Carcassi C, Font J, Passiu G, Smolen J, Papasteriades C, Houssiau F, Nebro AF, Ramon Garrido ED, Jedryka-Goral A, Marcolongo R. HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with sytemic lupus erythematosus. Lupus 2000;9:47-55.
22. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, de Silva A, Cook JT, Barnardo M, Cullen S, Welsh KI, Jewell DP. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122:854-866.
23. Achord JL, Gunn CH Jr, Jackson JF. Regional enteritis and HLA concordance in multiple siblings. Dig Dis Sci 1982;27:330-332.
24. Ardouin M, Urvoy M, Genetet B, Faucher R, Favennec F. Tissue groups and ophthalmology. Arch Ophtalmol (Paris) 1976;36:733-740.
25. Tanigaki N, Fruci D, Groome N, Butler RH, Londei M, Tosi R. Exploring myelin basic protein for HLA class I-binding sequences. Eur J Immunol 1994;24:2196-2202.
26. Mangalam AK, Khare M, Krco C, Rodriguez M, David C. Identification of T cell epitopes on human proteolipid protein and induction of experimental autoimmune encephalomyelitis in HLA class II-transgenic mice. Eur J Immunol 2004; 34:280-290.
27. Czaja AJ, Strettell MD, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R. Associations between alleles of the major histocompatibility complex and type I autoimmune hepatitis. Hepatology 1997;25:317-323.
28. Jaraquemada D, Ollier W, Awad I, Young A, Festenstein H. HLA and rheumatoid arthritis: Susceptibility or severity? Dis Markers 1986;4:43-53.
29. Sjoholm AG, Kjellman NI, Low B. C4 allotypes and HLA-DR antigens in the family of a patient with C4 deficiency. Clin Genet 1985;28:385-393.
30. Whittingham S, Mathews JD, Schanfield MS, Tait BD, Mackay IR. HLA and Gm genes in systemic lupus erythematosus. Tissue Antigens 1983;21:50-57.
31. Monplaisir N, Valette I, Pierre-Louis S, Yoyo M, Sobesky G, Verpre FC, Quist D, Arfi S, Gervaise G, Gabriel JM, et al. Study of HIA antigens in systemic lupus erythematosus in the French West Indies. Tissue Antigens 1988;31:238-242.
32. Soppi E, Eskola J, Lehtonen A. Evidence against HLA and immunological dependence of disease outbreak in SLE. Immunological characterisation of identical twins clinically discordant for SLE. Ann Rheum Dis 1985;44:45-49.
33. Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Lohr HF, Schneider PM, Meyer zum Buschenfelde KH, Rittner C. HLA-DRB*11301 and *1302 protect against chronic hepatitis B. J Hepatol 1997;26:503-507.
34. Spellberg B, Edwards JE Jr. Typel/Type 2 immunity in infectious diseases. Clin Infect Dis 2001;32:76-102.
35. Sidney J, Southwood S, Mann DL, Fernandez-Vena MA, Newman MJ, Sette A. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 2001;62:1200-1216.
36. Sandberg-Wollheim M. Optic neuritis: Studies on the cerebrospinal fluid in relation to clinical course in 61 patients. Acta Neurol Scand 1975;52:167-178, 26 {pleocytosis in half the ON patients}.
37. Sorensen TL, Ransohoff RM, Jensen J, Sellebjerg F. Evidence favoring the involvement of CC chemokine receptor (CCR) 5 in T-lymphocyte accumulation in optic neuritis. Acta Neurol Scand 2003;107:221-227.
38. Tsuchida T, Parker KC, Turner RV, McFarland HF, Coligan JE, Biddison WE. Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci USA 1994;91:10859-10863.
39. Crawford MP, Yan SX, Ortega SB, Mehta RS, Hewitt RE, Price DA, Stasny P, Douek DC, Koup RA, Racke MK, Karandikar NJ. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004;103:4222-4231.
40. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, Hjorth P, Sondergaard L, Svejgaard A, Wucherpfennig K, Stuart DI, Bell JI, Jones EY, Fugger L. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002;3:940-943.
41. Haegert DG, Swift FV, Benedikz J. Evidence for a complex role of HLA class II genotypes in susceptibility to multiple sclerosis in Iceland. Neurology 1996;46:1107-1111.
42. Ford DK, da Roza DM, Ward RH. Arthritis confined to knee joints. Synovial lymphocyte responses to microbial antigens correlate with distribution of HLA. Arthritis Rheum 1984;27:1157-1164.
43. Tan LC, Mowat AG, Fazou C, Rostron T, Roskell H, Dunbar PR, Tournay C, Romagne F, Peyrat MA, Houssaint E, Bonneville M, Rickinson AB, McMichael AJ, Callan MF. Specificiiy of T cells in synovial fluid: High frequencies of CD8(+) T cells that are specific for certain viral epitopes. Arthritis Res 2000;2:154-164.
44. Snijders A, Elferink DG, Geluk A, van Der Zanden AL, Vos K, Schreuder GM, Breedveld FC, de Vries RR, Zanelli EH. An HLA-DRB1-derived peptide associated with protection against rheumatoid arthritis is naturally processed by human APC's. J Immunol 2001;166:4987-4993.
45. Fineschi S. Can recombinant anti-hepatitis B vaccine be a cause of systemic lupus erythematosus? Lupus 2001;10:830.
46. Smikle MF, Barton EN, DeCeulaer K, Williams WN, James OB. Systemic lupus erythematosus, rheumatoid arthritis and HLA phenotypes in Jamaicans. West Indian Med J 1995;44:11-13.
47. Vitali C, Tavoni A, Rizzo G, Neri R, D'Ascanio A, Cristofani R, Bombardieri S. HLA antigens in Italian patients with primary Sjogren's syndrome. Ann Rheum Dis 1986;45:412-416.
48. Camps Garcia MT, Ocon Sanchez P, Alonso Ortiz A, Belmonte, Lopez MA, Garcia Portales R, Frutos Sanz MA, Guil Garcia M, de Ramon Garrido E. Class I and II HLA antigens in patients with systemic lupus erythematosus in the south of Spain. Med Clin(Barc) 1994;102:688-693.
49. Goldstein R, Moulds JM, Smith CD, Sengar DP. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1996;23:1173-1179.
50. Kang HI, Fei HM, Saito I, Sawada S, Chen SL, Yi D, Chan E, Peebles C, Bugawan TL, Erlich HA, et al. Comparison of HLA class II genes in Caucasoid. Chinese and Japanese patients with primary Sjogren's syndrome. J Immunol 1993;150:3615-3623.
51. Modena V, Amoroso A, Frattasio C, Pera A, Costantini P, Maiocco I, Ponti V, Di Vittorio CC, Verme G, Curtoni ES. HLA antigens and clinical manifestations in Crohn's disease. Clin Exp Rheumatol 1988;6:221-225.
52. Ferrara GB, Martinetti M, et al. [Italian HLA DRB1*04] Gjertson DW, Geer L, Lee SH, Kawata J, Sutrisno R. In: Terasaki PI, Gjertson DW, editors. Population Studies. Los Angeles: HLA 1997 UCLA Tissue Typing Laboratory; 1997. p 234-238.
53. Toussirot E, Darmon P, Reviron D, Mercier P, Acquaviva PC. Erosive polyarthritis and Crohn's disease. A case with HLA DRB1 determination. Clin Exp Rheumatol 1995;13:255-257.
54. Trachtenberg EA, Yang H, Hayes E, Vinson M, Lin C, Targan SR, Tyan D, Erlich H, Rotter JI. HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations. Hum Immunol 2000;61:326-333.
55. Black CM, Welsh KI, Fielder A, Hughes GR, Batchelor JR. HLA antigens and Bf allotypes in SLE: Evidence for the association being with specific haplotypes. Tissue Antigens 1982;19:115-120.
56. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeers PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-28.
57. Vermiere S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125:32-39.
58. Sarzi-Puttini P, Ardizzone S, Manzionna G, Atzeni F, Colombo E, Antivalle M, Carrabba M, Bianchi-Porro G. Infliximab-induced lupus in Crohn's disease: A case report. Dig Liver Dis 2003;35:814-817.
59. Spickett G. Connective tissue diseases. In: Spickett G, editor. Oxford handbook of clinical immunology. New York: Oxford University Press Inc. 1999. p 292-296.
60. Viallard JF, Boiron JM, Parrens M, Moreau JF, Ranchin V, Reiffers J, Leng B, Pellegrin JL. Severe pancytopenia triggered by recombinant hepatitis B vaccine. Br J Haematol 2000;110:230-233.
61. Snijders A, Elferink DG, Geluk A, van Der Zanden AL, Vos K, Schreuder GM, Breedveld FC, deVries RR, Zanelli EH. An HLA-DRB1-derived peptide associated with protection against rheumatoid arthritis is naturally processed by human APC's. J Immunol 2001;166:4087-4093.
62. Wilmshurst JM, Pohl KR, Vaughan RW, Hughes RA. Familial Guillain-Barre syndrome. Eur J Neurol 1999;6:499-503.
63. Spencer SJ, Burns A, Gaskin G, Pusey CD, Rees AJ. HLA class II specificities in vasculitis with antibodies to neutrophil. cytoplasmic antigens. Kidney Int 1992;41:1059-1063.
64. Sany J. Clinical and biological polymorphism of rheumatoid arthritis. Clin Exp Rheumatol 1994;(Suppl 11):S59-S61.
65. Zanelli E, Breedveld FC, de Vries RR. HLA association with autoimmune disease: A failure to protect? Rheumatology (Oxford) 2000;39:1060-1066.
66. Papiha SS, Murry G, Ad'Hia A, Mains BT, Venning M. Association of Wegener's granulomatosis with HLA antigens and other genetic markers. Ann Rheum Dis 1992;51:246-248.
67. Orchard TR, Thyagaraja S, Welsh KI, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000;118:274-278.
68. Plevy SE, Targan SR, Yang H, Fernandez D, Rotter JI, Toyoda H. Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology 1996;110:1053-1060.
69. Igarashi M, Sucia-Foca N, Ferrone S. Differential expression of HLA-DR allospecificities on antigen specific T cell clones. Tissue Antigens 1987;29:160-167.
70. Modica MA, Zambito AM, Candore G, Caruso C. Markers of T lymphocyte activation in HLA-B8, DR3 positive individuals. Immunobiology 1990;181:257-266.
71. De Maeyer E, De Maeyer-Guignard J. Interferons. In: Thomson A editor. The cytokine handbook. 3rd ed. 1998. p 494-496.
72. Pope JE, Stevens A, Howson W, Bell DA. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J Rheumatol 1998;25:1687-1693.
73. Hashemi-Tavoularis S, Fitzpatrick J, Keon PA, Roy R [Canadian HILA DRB1] Gjertson, DW, Geer, L, Lee, SH, Kawata J, Sutrisno, R. Population Studies. In: Terasald PI, Gjertson DW, editors. HLA 1997. UCLA Tissue Typing Laboratory; 1997. Los Angeles 333-335.
74. Silverberg MS, Mirea L, Bull SB, Murphy JE, Steinhart AH, Greenberg GR, McLeod RS, Cohen Z, Wade JA, Siminovitch KA. A population- and family-based study of Canadian families reveals association of HLA DRB1*0103 with colonic involvement in inflammatory bowel disease. Inflamm Bowel Dis 2003;9:1-9.
75. Gibert M, Balandraud N, Touinssi M, Mercier P, Roudier J, Reviron D. Functional categorization of HLA-DRB1 alleles in rheumatoid arthritis: The protective effect. Hum Immunol 2003;64:930-935.
76. Rosloniec EF, Whittington KB, Zaller DM, Kang AH. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol 2002; 168:253-259.
77. Vos K, Miltenburg AM, van Meijgaarden KE, van den Heuvel M, Elferink DG, van Galen PJ, van Hogezand RA, van Vliet-Daskalopoulou E, Ottenhoff TH, Breedveld FC, Boots AM, de Vries RR. Cellular immune response to human cartilage glycoprotein-39 (HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory conditions. Rheumatology (Oxford) 2000;39:1326-1331.
78. Steere AC, Gross D, Meyer AL, Huber BT. Autoimmune mechanisms in antibiotic treatment-resistant Lyme arthritis. J Autoimmun 2001;16:263-268.
79. Muraro PA, Vergelli M, Kalbus M, Banks DE, Nagle JW, Tranquill LR, Nepom GT, Biddison WE, McFarland HF, Martin R. Immunodominance of a low-affinity major histocompatibility complex-binding myelin basic protein epitope (residue 111-129) in HLA-DR4 (B1*0401) subjects is associated with a restricted T cell receptor repertoire. J Clin Invest 1997;100:339-349.
80. Greening JE, Tree TI, Kotowicz KT, van Halteren AG, Roep BO, Klein NJ, Peakman M. Processing of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T-cells. Diabetes 2003;52:717-725.
81. Pascual M, Mataran L, Jones G, Shing D, van der Slik AR, Giphart MJ, Schreuder GM, de Vries RR, Breedveld FC, Roovers E, Zanelli E, Martin J. HLA haplotypes and susceptibility to rheumatoid arthritis. More than class II antigens. Scand J Rheumatol 2002;31:275-278.
82. Nakken B, Jonsson R, Brokstad KA, Omholt K, Nerland AH, Haga HJ, Halse AK. Associations of MHC class II alleles in Norwegian primary Sjogren's syndrome patients: Implications for development of autoantibodies to the Ro52 autoantigen. Scand J Immunol 2001;54:428-433.
83. Grant SF, Kristjansdottir H, Steinsson K, Blondal T, Yuryev A, Stefansson K, Gulcher JR. Long PCR detection of the C4A null allele in B8-C4AQ0-C4B1-DR3. J Immunol Methods 2000;244:41-47.
84. de Jong BA, Huizinga TW, Zanelli E, Giphart MJ, Bollen EL, Uitdehaag BM, Polman CH, Westendorp RG. Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region. Neurology 2002;59:549-555.
85. Massa M, Mazzoli F, Pignatti P, De Benedetti F, Passalia M, Viola S, Samodal R, La Cava A, Giannoni F, Ollier W, Martini A, Albani S. Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2721-2729.
86. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups [Canadian (B, DR, DQ)]. In: Tsuji K, Aizawa M, Sasazuki T, editors. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference, New York: Oxford University Press; 1992; 1: 1155.
87. Aaron S, Miller ML, Howard J, Fraser PA, Jackson JM, Larson MG, Glass DM. Complementation with HLA-A and HLA-D locus alleles in ankylosing spondylitis with preipheral arthritis. J Rheumatol 1985;12:553-557.
88. Puttick AH, Briggs DC, Welsh KI, Vaughan R, Williamson EA, Boyce M, Jacoby RK, Jones VE. Genes associated with rheumatoid arthritis and mild inflammatory arthritis. I. Major histocompatibility complex class I, II and III allotypes. Ann Rheum Dis 1990;49:219-224.
89. Ollier W, Silman A, Gosnell N, Currey H, Awad J, Doyle P, McCloskey D, Alonso A, Hossain MA, Festenstein H. HLA and rheumatoid arthritis: An analysis of multicase families. Dis Markers 1986;4:85-98.
90. Khan MA. B7-CREG and ankylosing spondylitis. Br J Rheumatol 1983;22(4 Suppl 2):129-133.
91. Sibiriakova LG, Iandashevskaia SI, Pevnitskii LA. Analysis of distribution of histocompatibility antigens class I and II in children with rheumatoid arthritis. Revmatologiia (Mosk) 1989;(2):23-26.
92. Sels F, Westhovens R, Emonds MP, Vandermeulen E, Dequeker J. HJA typing in a large family with multiple cases of different autoimmune diseases. J Rheumatol 1997;24:856-859.
93. Biemend I, Burnham WR, D'Amaro J, Langman MJ. HLA-A and -B antigens in inflammatory bowel disease. Gut 1986; 27:934-941.
94. Kinouchi Y, Matsumoto K, Negoro K, Takagi S, Takahashi S, Hiwatashi N, Shimosegawa T Hla-B genotype in Japanese patients with Crohn's disease. Dis Colon Rectum 2003;46(10 Suppl):S10-S14.
95. Fujita K, Naito S, Okabe N, Yao T. Immunological studies in Crohn's disease I. Association with HLA systems in the Japanese. J Clin Lab Immunol 1984;14:99-102.
96. Petrovsky N, Harrison LC. HLA class II-associated polymorphism of interferon-gamma production. Implications for HLA-disease association. Hum Immunol 1997; 53:12-16.
97. Takahashi Y, Ametani A, Totsuka M, Kaminogawa S. Autocrine B-cell stimulation by interleukin-2 during a cognate interaction with T-cells. Immunol Lett 1999;65:183-188.
98. Rasmussen HB, Kelly MA, Clausen J. Additive effect of the HLA-DR15 haplotype on susceptibility to multiple sclerosis. Mult Scler 2001;7:91-93.
99. Ruberti G, Begovich AB, Steere AC, Klitz W, Erlich HA, Fathman CG. Molecular analysis of the role of the HLA class II genes DRB1, DQA1, DQB1 and DPB1 in susceptibility to Lyme arthritis. Hum Immunol 1991;31:20-27.
100. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups [A allele frequencies]. In: Tsuji K, Aizawa M, Sasazuki T, editors. HLA 1991 Proceedings of the Eleventh International Histocompatibility Workshop and Conference, New York: Oxford University Press; 1992, 1: 1067-1068.
101. Bodmer JG, Marsh SGE, Albert ED, et al. In: Terasaki PI, Gjertson DW, editors. Nomenclature for factors of the HLA system, 1996. Los Angeles: HLA 1997 UCLA Tissue Typing Laboratory; 1997. p 137.
102. Price P, Witt C, Allcock R, Sayer D, Garlepp M, Kok CC, French M, Mallal S, Christiansen F. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol Rev 1999;167:257-274.
103. Kondo A, Sidney J, Southwood S, del Guercio MF, Appella E, Sakamoto H, Grey HM, Celis E, Chesnut RW, Kubo RT, Sette A. Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding motifs. Immunogenetics 1997;45:249-258.
104. Provenzano M, Lim JB, Mocellin S, Monsurro V, Bettinotti M, Marincola FM, Stroncek DF. The matrix protein pp65(341-350): A peptide that induces ex vivo stimulation and in vitro expansion of CMV-specific CD8+ T cells in subjects bearing either HLA-A*2402 or A*0101 allele. Transfusion 2003;43:1567-1574.
105. Shankarkumar U, Ghosh K, Badakere S, Mohanty D. Novel HLA class I alleles associated with Indian leprosy patients. J Biomed Biotechnol 2003;2003:208-211.
106. Suzuki H, Sata M, Yano Y, Hidaka R, Sasaki E, Abe H, Toyonaga J, Tanikawa K. A case of chronic hepatitis B with Crohn's disease. Nippon Shokakibyo Gakkai Zasshi 1986;83:1387-1391.
107. Cottone M, Magliocco A, Trallori G, Brignola C, Vandelli C, Ardizzone S, Meucci G, Zannoni F, Di Maio G, Astegiano M. Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis. Ital J Gastroenterol 1995;27:3-4.
108. Sipetic S, Vlajinac H, Kocev N, Marinkovic J, Radmanovic S, Denic L. Family history and risk of type I diabetes mellitus. Acta Diabetol 2002;39:111-115.
109. Mader R, Segol O, Adawi M, Trougoboff P, Nussinson E. Arthritis or vasculitis as presenting symptoms of Crohn's disease. Rheumatol Int 2004; [Epub ahead of print].
110. Yacyshyn B, Meddings L Sadowski D, Bowen-Yacyshyn MB. Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability. Dig Dis Sci 1996;41:2493-2498.
111. de la Fuente-Fernandez R, Rubio-Nazabal E, de la Inglesia-Martinez F. Guillain-Barre syndrome as an extraintestinal manifestation of Crohn's disease. Postgrad Med J 1995; 71:437-438.
112. Sinsawaiwong S, Thampanitchawong P. Guillain-Barre syndrome following recombinant hepatitis B vaccine and literature review. J Med Assoc Thai 2000;83:1124-1126.
113. Probert CS, Chott A, Turner JR, Saubermann LJ, Stevens AC, Bodinaku K, Elson CO, Balk SP, Blumberg RS. Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol 1996;157:3183-3191.
114. Ruthlein J, Ibe M, Burghardt W, Mossner J, Auer IO. Immunoglobulin G (IgG), IgG1 and IgG2 determinations from endoscopic biopsy specimens in control, Crohn's disease and ulcerative colitis subjects. Gut 1992; 33:507-512.
115. Korber J, Kottgen E, Renz H. A case of Crohn's disease with increased CD8 T-cell activation and remission during therapy with intravenous immunoglobulins. Scand J Gastroenterol 1998;33:1113-1117.
116. Thuraisingam A, Leiper K. Medical management of Crohn's disease. Hosp Med 2003;64:713-718.
117. Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostolaki M, Pizarro T, Kotlyarov A, Forster I, Flavell R, Gaestel M, Tsichlis P, Cominelli F, Kollias G. Genetic Dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002;196:1563-1574.
118. Bisping G, Lugering N, Lutke-Brintrup S, Pauels HG, Schurmann G, Domschke W, Kucharzik T. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells. Clin Exp Immunol 2001;123:15-22.
119. Cornet A, Savidge TC, Cabarrocas J, Deng WL, Colombel JF, Lassmann H, Desreumaux P, Liblau RS. Enterocolitis induced by autoimmune targeting of enteric glial cells: A possible mechanism in Crohn's disease? Proc Natl Acad Sci USA 2001;98:133306-133311.
120. Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, Imada A, Binion DG, Musso A, West GA, Dobrea GM, McCormick TS, Lapetina EG, Levine AD, Ottaway CA, Fiocchi C. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl/Bax mucosal imbalance. J Immunol 1999;163:1081-1090.
121. Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998;95:9979-9984.
122. Becker KG. Comparative genetics of type I diabetes and autoimmune disease: Common loci, common pathways? Diabetes 1999;48:1353-1358.
123. Tanaka A, Igarashi M, Kakinuma M, Oh-i T, Koga M, Okuda T. The occurrence of various collagen diseases in one family: A sister with ISSc, PBC, APS and SS and a brother with systemic lupus erythematosus. J Dermatol 2001;28:547-553.
124. Fennessy M, Metcalfe K, Hitman GA, Niven M, Biro PA, Tuomilehto J, Tuomilehto-Wolf E. A gene in the HLA class I region contributes to susceptibility to IDDM in the Finnish population. Childhood diabetes in Finland (DiMe) study group. Diabetologia 1994;37:937-944.
125. Bettinotti MP, Hartung K, Deicher H, Messer G, Keller E, Weiss EH, Albert ED. Polymorphism of the tumor necrosis factor beta gene in systemic lupus erythematosus: TNFB-MHC haplotypes. Immunogenetics 1993;37:449-454.
126. Madigand M, Oger JJ, Fauchet R, Sabouraud O, Genetet B. HLA profiles in multiple sclerosis suggest two forms of the disease and the existence of protective haplotypes. J Neurol Sci 1982;53:519-529.
127. Kankonkar S, Jeyanti G, Singal BS, Shankarkumar U. Evidence for novel DRB1*15 allele association among clinically definite multiple sclerosis patients from Mumbai, India. Hum Immunol 2003; 64:478-482.
128. Runmarker B, Martinsson T, Wahlstrom J, Andersen O. HLA and prognosis in multiple sclerosis. J Neurol 1994; 241:385-390.
129. Wandinger KP, Trillenberg P, Kluter H, Wessel K, Kirchner H. Clinical and molecular findings in multiple sclerosis patients with type I diabetes mellitus. J Clin Neurosci 1999;6:373-374.
130. Hao Q, Saida T, Kawakami H, Mine H, Maruya E, Inoko H, Saji H. HLAs and genes in Japanese patients with multiple sclerosis: Evidence for the increased frequencies of HLA-Cw3, HLA-DR2, and HLA-DQB1*0602. Hum Immunol 1992;35:116-124.
131. Nomura K. Guillain-Barre syndrome: Clinical features, immune mechanisms, and therapies. Rinsho Shinkeigaku 1996;36:1367-1369.
132. Nakajima A, Matsuhashi N, Kodama T, Yazaki Y, Takazoe M, Kimura A. HLA-linked susceptibility genes in Crohn's disease. Gastroenterology 1995;109:1462-1467.
133. Reinshagen M, Loeliger C, Kuehnl P, Weiss U, Manfras BJ, Adler G, Boehm BO. HLA class II gene frequencies in Crohn's disease: A population based analysis in Germany. Gut 1996;38:538-542.
134. Noelle RJ, Erickson LD. Determinations of B cell fate in immunity and autoimmunity. Curr Dir Autoimmun 2005; 8:1-24.
135. Merelli E, Casoni F. Prognostic factors in multiple sclerosis: Role of intercurrent infections and vaccinations against influenza and hepatitis B. Neurol Sci 2000;21:S853-S856.
136. Monteyne P, Andre FE. Is there a causal link between hepatitis B vaccination and multiple sclerosis? Vaccine 2000;18:1994-2001.
137. Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: A prospective study. Neurology 2004;63:838-842.
138. Kaplanski G, Retornaz F, Durand J, Soubeyrand J. Central nervous system demyelination after vaccination against hepatitis B and HLA haplotype. J Neurol Neurosurg Psychiat 1995;58:758-759.
139. Boiko AN, Favorova OO. Multiple sclerosis: Molecular and cellular mechanisms. Mol Biol (Mosk) 1995;29:727-749.
140. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: A modifying influence of HLA class I genes in an HLA class II associated disease. Tissue Antigens 2000;55:140-148.
141. Weinshenker BG, Santrach P, Bissonet AS, McDonnell SK, Schaid D, Moore SB, Rodriguez M. Major histocompatibility complex class II alleles and the course and outcome of MS: A population-based study. Neurology 1998;51:742-747.
142. Renard JL, Guillamo JS, Ramirez JM, Thillia H, Felten D, Buisson Y. Acute transverse cervical myelitis following hepatitis B vaccination. Evolution of anti-HBs antibodies. Presse Med 1999;28:1290-1292.
143. Lindsey JW, Albers GW, Steinman L. Recurrent transverse myelitis, myasthenia gravis and autoantibodies. Ann Neurol 1992;32:407-409.
144. Monos DS, Papaioakim M, Ho TW, Li CY, McKhann GM. Differential distribution of HLA alleles in two forms of Guillain-Barre syndrome. J Infect Dis 1997;176(Suppl 2): S180-S182.
145. Ang CW, van Doorn PA, Endtz HP, Merkies IS, Jacobs BC, de Klerk MA, van Koningsveld R, van der Meche FG. A case of Guillain-Barre syndrome following a family outbreak of Campylobacter jejuni enteritis. J Neuroimmunol 2000;111:229-233.
146. Soen Y, Chen DS, Kraft DL, Davis MM, Brown PO. Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLOS Biol 2003;1:E65, (Epub 2003 Dec 22).
147. Consolandi C, Frosini A, Pera C, Ferrara GB, Bordoni R, Castiglioni B, Rizzi E, Mezzelani A, Bernardi LR, De Bellis G, Battaglia C. Polymorphism analysis within the HLA-A locus by universal oligonucleotide array. Hum Mutat 2004;24:428-434.
148. Li AX, Seul M, Cicciarelli J, Yang JC, Iwaki Y. Multiplexed analysis of polymorphisms in the HLA gene complex using bead array chips. Tissue Antigens 2004;63:518-528.
149. Ringquist S, Alexander AM, Styche A, Pecoraro C, Rudert WA, Trucco M. HLA class II DRB high resolution genotyping by pyrosequencing: Comparison of group specific PCR and pyrosequencing primers. Hum Immunol 2004;65:163-174.